Gut Microbial Diversity in Female Patients With Invasive Mole and Choriocarcinoma and Its Differences Versus Healthy Controls.
choriocarcinoma
gestational trophoblastic neoplasia
gut microbiota
invasive mole
microbiome
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
05
2021
accepted:
09
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
21
10
2021
Statut:
epublish
Résumé
To investigate variation in gut microbiome in female patients with invasive mole (IM) and choriocarcinoma (CC) and compare it with healthy controls. Fecal microbiome of 12 female patients with IM, 9 female patients with CC, and 24 healthy females were analyzed based on 16s rDNA sequencing. Alpha (α) diversity was evaluated using Shannon diversity index and Pielou evenness index, while beta (β) diversity was assessed using principle coordinate analysis (PCoA) of unweighted Unifrac distances. The potential functional changes of microbiomes were predicted using Tax4Fun. The relative abundance of microbial taxa was compared using Welch's t test. The role of varied gut microbiota was analyzed The α diversity and β diversity were significantly different between IM patients and controls, but not between CC patients and controls. In addition, the abundance of cancer-related genes was significantly increased in IM and CC patients. Notably, a total of 19 families and 39 genera were found to have significant differences in bacterial abundance. ROC analysis indicated that Our study demonstrated that the diversity and composition of gut microbiota among IM patients, CC patients, and healthy females were significantly different, which provides rationale for using gut microbiota as diagnostic markers and treatment targets, as well as for further study of gut microbiota in gestational trophoblastic neoplasia (GTN).
Identifiants
pubmed: 34513727
doi: 10.3389/fcimb.2021.704100
pmc: PMC8428518
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
704100Informations de copyright
Copyright © 2021 Liu, Pan, Liu and Ma.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Crit Rev Oncol Hematol. 2021 Jan;157:103165
pubmed: 33227575
Genomics Proteomics Bioinformatics. 2018 Feb;16(1):33-49
pubmed: 29474889
Gynecol Oncol. 2020 Nov;159(2):299-308
pubmed: 32933758
ISME J. 2016 Jan;10(1):170-82
pubmed: 26090993
BMC Genomics. 2020 Apr 7;21(1):286
pubmed: 32264859
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4586-91
pubmed: 20571116
Bioinformatics. 2015 Sep 1;31(17):2882-4
pubmed: 25957349
Cancers (Basel). 2020 Sep 06;12(9):
pubmed: 32899975
Nat Rev Immunol. 2016 May 27;16(6):341-52
pubmed: 27231050
Ann Oncol. 2013 Oct;24 Suppl 6:vi39-50
pubmed: 23999759
Gut. 2012 Apr;61(4):543-53
pubmed: 22110050
Ageing Res Rev. 2020 Dec;64:101164
pubmed: 32977058
Lancet Oncol. 2019 Feb;20(2):e77-e91
pubmed: 30712808
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Physiology (Bethesda). 2016 Jul;31(4):283-93
pubmed: 27252163
Int J Gynaecol Obstet. 2009 Apr;105(1):3-4
pubmed: 19322933
AMB Express. 2019 Mar 23;9(1):40
pubmed: 30904962
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
Elife. 2013 Nov 05;2:e01202
pubmed: 24192039
Front Immunol. 2017 Mar 29;8:354
pubmed: 28424690
Cancer Cell. 2018 Apr 9;33(4):570-580
pubmed: 29634945
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Periodontol 2000. 2011 Feb;55(1):36-47
pubmed: 21134227
Nucleic Acids Res. 2007;35(21):7188-96
pubmed: 17947321
Sci Rep. 2017 Oct 5;7(1):12722
pubmed: 28983086
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Am J Obstet Gynecol. 2010 Dec;203(6):531-9
pubmed: 20728069
J Exp Med. 2020 May 4;217(5):
pubmed: 32142585
Gynecol Oncol. 2015 Jul;138(1):190-200
pubmed: 25957158
Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:42-52
pubmed: 33422446
J Med Internet Res. 2018 Sep 24;20(9):e10897
pubmed: 30249575
Placenta. 2021 Feb 25;:
pubmed: 33685753
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Immunity. 2015 May 19;42(5):965-76
pubmed: 25992865
BMC Biol. 2019 Oct 28;17(1):83
pubmed: 31660948
Gynecol Oncol. 2019 Nov;155(2):237-244
pubmed: 31500892
J Natl Compr Canc Netw. 2019 Nov 1;17(11):1374-1391
pubmed: 31693991
Am J Obstet Gynecol. 2007 Feb;196(2):172.e1-5
pubmed: 17306669
Nat Immunol. 2013 Jul;14(7):676-84
pubmed: 23778795
Nat Methods. 2013 Jan;10(1):57-9
pubmed: 23202435
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16
pubmed: 25341573
Front Immunol. 2019 Jun 27;10:1466
pubmed: 31316514
Int J Gynecol Cancer. 2016 Feb;26(2):367-70
pubmed: 26588240
Cell. 2016 May 5;165(4):842-53
pubmed: 27133167
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502